Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem Inc. demonstrates a positive outlook due to the promising efficacy of its pipeline, particularly with binimetinib and VS-7375, which show enhanced response rates and strong physician support in both academic and community oncology settings. The company's focus on combining treatments has the potential to improve patient outcomes, as demonstrated by advanced results in non-small cell lung cancer (NSCLC) and the KRAS G12D landscape, which is pivotal for expanding their market share. Additionally, the lower treatment discontinuation rates compared to historical MEK inhibitors further solidify Verastem's position as a credible contender in the competitive oncology sector, suggesting a strong foundation for sustained growth.

Bears say

Verastem Inc has consistently reported operating losses since its founding and may require several years to achieve profitability, indicating significant financial challenges ahead. The company's focus on KRAS inhibitors faces hurdles due to lower overall response rates in certain patient populations, particularly evident in colorectal cancer, which may hinder market acceptance and revenue generation. Additionally, potential delays in regulatory approvals for their treatments could further depress the company’s stock value, reflecting ongoing uncertainties in their clinical and commercial prospects.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.